2,833 publications from this institution
info:eu-repo/semantics/nonPublished
To the Editor: In this issue of the Journal, Warren et al.1 and Siegel2 offer their views on the approval of drotrecogin alfa (activated), or recombinant human activated protein C, for the treatment of severe sepsis. We concur with Dr. Siegel's comments regarding the extensive testing to ensure the potency and consistency of drotrecogin alfa (activated) used in the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.3 It is fortunate that the master cell bank used to produce the drug administered in the latter portion of the trial will be sufficient to meet clinical needs for . . .
Specific patterns of vCSF DAMP expression differentiated between traumatic and nontraumatic types of ABI and were associated with increased episodes of severe intracranial hypertension.
Abstract Rationale: As with other forms of interstitial lung disease (ILD), patients with connective tissue disease-associated ILD (CTD-ILD) require comprehensive, longitudinal monitoring of symptoms, physiological parameters, and imaging to accurately assess disease progression, evaluate therapeutic response, and enable timely detection of changes in disease severity.Remote monitoring using patient-recorded spirometry and Patient-Reported Outcome Measures (PROMs) offers a way to closely track changes in clinical status for individuals with ILD, allowing for timely interventions and better support during in-person appointments. Although studies have demonstrated concordance between remote and in-hospital spirometry measurements, remote monitoring has not yet been widely integrated into routine clinical practice. This research study was conducted to learn more about CTD-ILD patient and clinician adherence and acceptance of remote monitoring and to assess readability and acceptance of an electronic version of the Living with Pulmonary Fibrosis questionnaire (L-PF) recorded on a mobile device-based remote monitoring platform. Methods: Prospective, observational study of CTD-ILD patients (diagnosis according to American College of Rheumatology criteria). Patients were randomised to record home spirometry between 1 and 4 times per week for 90 days using a digital health application & Bluetooth-linked spirometer and complete the L-PF questionnaire weekly in the application. The data was available for clinician review in real time and monitored bi-weekly or monthly by their clinicians. Feasibility was assessed using patient adherence to prescribed measurements and patients’ perceptions of utility and acceptability of the platform via questionnaire. Results: 20 CTD-ILD patients consented and 15/20 provided ≥1 spirometry reading and were included in the analysis of adherence. 5/10 female; age 61 years (± 13.2). Adherence is displayed in the table below. Conclusions: This study found that CTD-ILD patients assigned to once or twice-weekly spirometry showed the highest adherence rates, with the 2x/week group achieving 76.92% adherence to expected readings and recording at least one reading 87.69% of weeks. In contrast, adherence declined in the 3x/week and 4x/week groups. These findings suggest that lower-frequency monitoring may better support patient adherence in remote ILD management.
